|
US5948786A
(en)
|
1996-04-12 |
1999-09-07 |
Sumitomo Pharmaceuticals Company, Limited |
Piperidinylpyrimidine derivatives
|
|
JP2003528144A
(ja)
|
2000-03-24 |
2003-09-24 |
ファーマジーン ラボラトリーズ リミテッド |
頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ
|
|
HN2001000224A
(es)
|
2000-10-19 |
2002-06-13 |
Pfizer |
Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
|
|
GB0031302D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
GB0031295D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Naphthalene derivatives
|
|
GB0103269D0
(en)
|
2001-02-09 |
2001-03-28 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
EP1494667A1
(en)
|
2002-04-12 |
2005-01-12 |
Pfizer Japan Inc. |
Imidazole compounds as anti-inflammatory and analgesic agents
|
|
EP1495005A1
(en)
|
2002-04-12 |
2005-01-12 |
Pfizer Japan Inc. |
Pyrazole compounds as anti-inflammatory and analgesic agents
|
|
JP2006506327A
(ja)
|
2002-05-23 |
2006-02-23 |
セラテクノロジーズ インコーポレイティド |
プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
|
|
CN100408570C
(zh)
|
2003-01-29 |
2008-08-06 |
阿斯特兰德英国有限公司 |
Ep4受体拮抗剂
|
|
TW200519116A
(en)
|
2003-08-26 |
2005-06-16 |
Teijin Pharma Ltd |
Pyrrolopyrimidine derivatives
|
|
AP2006003534A0
(en)
|
2003-09-03 |
2006-04-30 |
Pfizer |
Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
|
|
EP1678147B1
(en)
|
2003-09-15 |
2012-08-08 |
Lead Discovery Center GmbH |
Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
|
|
GB0324269D0
(en)
|
2003-10-16 |
2003-11-19 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
WO2005080367A1
(en)
|
2004-02-12 |
2005-09-01 |
Pharmagene Laboratories Limited |
Ep2 receptor agonists
|
|
BRPI0510666A
(pt)
|
2004-05-04 |
2007-12-04 |
Pfizer |
compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
|
|
JP4054369B2
(ja)
|
2004-05-04 |
2008-02-27 |
ファイザー株式会社 |
オルト置換アリールまたはヘテロアリールアミド化合物
|
|
HN2005000795A
(es)
|
2004-10-15 |
2010-08-19 |
Aventis Pharma Inc |
Pirimidinas como antagonistas del receptor de prostaglandina d2
|
|
AU2006246930C1
(en)
|
2005-05-19 |
2012-01-19 |
Merck Canada Inc. |
Quinoline derivatives as EP4 antagonists
|
|
WO2006128129A2
(en)
|
2005-05-26 |
2006-11-30 |
Synta Pharmaceuticals Corp. |
Method for treating cancer
|
|
AR060403A1
(es)
|
2006-04-12 |
2008-06-11 |
Sanofi Aventis |
Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
|
|
JP5244091B2
(ja)
|
2006-04-24 |
2013-07-24 |
メルク カナダ インコーポレイテッド |
Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
|
|
EP2035376B1
(en)
|
2006-06-12 |
2014-08-27 |
Merck Canada Inc. |
Indoline amide derivatives as ep4 receptor ligands
|
|
US20080280891A1
(en)
|
2006-06-27 |
2008-11-13 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents and uses thereof
|
|
WO2008008059A1
(en)
|
2006-07-12 |
2008-01-17 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents ans uses thereof
|
|
CA2657227A1
(en)
|
2006-07-14 |
2008-01-17 |
Novartis Ag |
Pyrimidine derivatives as alk-5 inhibitors
|
|
EP2054401B1
(en)
|
2006-08-11 |
2013-05-01 |
Merck Canada Inc. |
Thiophenecarboxamide derivatives as ep4 receptor ligands
|
|
WO2008039882A1
(en)
|
2006-09-30 |
2008-04-03 |
Sanofi-Aventis U.S. Llc |
A combination of niacin and a prostaglandin d2 receptor antagonist
|
|
WO2008104055A1
(en)
|
2007-02-26 |
2008-09-04 |
Merck Frosst Canada Ltd. |
Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
|
|
EP2141147A1
(en)
|
2007-03-26 |
2010-01-06 |
Astellas Pharma Inc. |
Ornithine derivative
|
|
CA2681146A1
(en)
|
2007-03-26 |
2008-10-02 |
Merck Frosst Canada Ltd. |
Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists
|
|
EP2014657A1
(de)
*
|
2007-06-21 |
2009-01-14 |
Bayer Schering Pharma Aktiengesellschaft |
Diaminopyrimidine als Modulatoren des EP2-Rezeptors
|
|
US20110028463A1
(en)
|
2007-07-03 |
2011-02-03 |
Astellas Pharma Inc. |
Amide compounds
|
|
CN101889004B
(zh)
|
2007-10-12 |
2014-09-10 |
阿斯利康公司 |
蛋白激酶抑制剂
|
|
CA2714743C
(en)
|
2008-02-19 |
2017-01-17 |
Janssen Pharmaceutica N.V. |
Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
|
|
SI2565191T1
(sl)
|
2008-05-14 |
2014-12-31 |
Astellas Pharma Inc. |
Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
|
|
US20130225528A1
(en)
|
2008-05-21 |
2013-08-29 |
Ariad Pharmaceuticals, Inc. |
Phosphorus Derivatives as Kinase Inhibitors
|
|
US8404736B2
(en)
|
2008-08-14 |
2013-03-26 |
Beta Pharma Canada Inc. |
Heterocyclic amide derivatives as EP4 receptor antagonists
|
|
CN102164942B
(zh)
|
2008-09-19 |
2017-02-15 |
生物科技研究有限公司 |
三萜系化合物及其使用的方法
|
|
JP2012503605A
(ja)
|
2008-09-25 |
2012-02-09 |
メルク カナダ インコーポレイテッド |
Ｅｐ４受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体
|
|
WO2011022348A1
(en)
|
2009-08-18 |
2011-02-24 |
Janssen Pharmaceutica Nv |
Ethylene diamine modulators of fatty acid amide hydrolase
|
|
WO2011063181A1
(en)
|
2009-11-23 |
2011-05-26 |
Lexicon Pharmaceuticals, Inc. |
Methods and assays for the treatment of irritable bowel syndrome
|
|
JP5607241B2
(ja)
|
2010-05-21 |
2014-10-15 |
ケミリア・エービー |
新規ピリミジン誘導体
|
|
PT2619182T
(pt)
|
2010-09-21 |
2017-01-17 |
Eisai R&D Man Co Ltd |
Composição farmacêutica
|
|
KR101857310B1
(ko)
|
2010-09-29 |
2018-05-11 |
가부시키가이샤 에누비 켄코우겡큐쇼 |
인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
|
|
BR112013012380A2
(pt)
|
2010-11-17 |
2016-08-30 |
Novartis Ag |
compostos 3-(aminoaril)-piridina
|
|
WO2012066065A1
(en)
|
2010-11-17 |
2012-05-24 |
Novartis Ag |
Phenyl-heteroaryl amine compounds and their uses
|
|
WO2012076063A1
(en)
|
2010-12-10 |
2012-06-14 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
WO2012103071A2
(en)
|
2011-01-25 |
2012-08-02 |
Eisai R&D Management Co., Ltd. |
Compounds and compositions
|
|
EP2688883B1
(en)
|
2011-03-24 |
2016-05-18 |
Noviga Research AB |
Pyrimidine derivatives
|
|
EP2702043A1
(en)
|
2011-04-29 |
2014-03-05 |
Exelixis, Inc. |
Inhibitors of inducible form of 6-phosphofructose-2-kinase
|
|
US9518044B2
(en)
|
2011-06-20 |
2016-12-13 |
Emory University |
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
|
|
US9181279B2
(en)
|
2011-07-04 |
2015-11-10 |
Rottapharm Biotech S.R.L. |
Cyclic amine derivatives as EP4 receptor antagonists
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
US20150004175A1
(en)
|
2011-12-13 |
2015-01-01 |
Yale University |
Compositions and Methods for Reducing CTL Exhaustion
|
|
RS61664B1
(sr)
|
2012-04-24 |
2021-04-29 |
Vertex Pharma |
Inhibitori dna-pk
|
|
JO3296B1
(ar)
|
2012-06-29 |
2018-09-16 |
Lilly Co Eli |
مركبات فينوكسي إيثيل بيبريدين
|
|
TWI572597B
(zh)
|
2012-06-29 |
2017-03-01 |
美國禮來大藥廠 |
二甲基－苯甲酸化合物
|
|
EP2711364A1
(en)
*
|
2012-09-21 |
2014-03-26 |
Chemilia AB |
4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
|
|
MY182386A
(en)
|
2012-11-27 |
2021-01-22 |
Thomas Helledays Stiftelse For Medicinsk Forskning |
Pyrimidine-2,4-diamine derivatives for treatment of cancer
|
|
UA115576C2
(uk)
|
2012-12-06 |
2017-11-27 |
Байєр Фарма Акцієнгезелльшафт |
Похідні бензимідазолу як антагоністи ер4
|
|
EP2765128A1
(en)
|
2013-02-07 |
2014-08-13 |
Almirall, S.A. |
Substituted benzamides with activity towards EP4 receptors
|
|
TW201443004A
(zh)
|
2013-02-15 |
2014-11-16 |
Lilly Co Eli |
苯氧基乙氧基化合物
|
|
TWI636046B
(zh)
|
2013-05-17 |
2018-09-21 |
美國禮來大藥廠 |
苯氧基乙基二氫－１ｈ－異喹啉化合物
|
|
SG11201510121RA
(en)
|
2013-06-12 |
2016-01-28 |
Kaken Pharma Co Ltd |
4-alkynyl imidazole derivative and medicine comprising same as active ingredient
|
|
AU2014315457B2
(en)
|
2013-09-04 |
2018-05-10 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
JP6521977B2
(ja)
|
2013-09-06 |
2019-05-29 |
オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
免疫調節剤としての１，２，４−オキサジアゾール誘導体
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
CN105636958B
(zh)
|
2013-10-17 |
2018-01-05 |
沃泰克斯药物股份有限公司 |
Dna‑pk抑制剂
|
|
SI3424920T1
(sl)
|
2013-10-17 |
2020-08-31 |
Vertex Pharmaceuticals Incorporated |
Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
|
|
SI3083554T1
(sl)
|
2013-12-17 |
2019-04-30 |
Eli Lilly & Company |
Spojine dimetilbenzojske kisline
|
|
DK3083562T3
(da)
|
2013-12-17 |
2017-11-13 |
Lilly Co Eli |
Cykliske phenoxyethylaminderivater og deres aktivitet som EP4-receptormodulatorer
|
|
TW201607943A
(zh)
|
2013-12-19 |
2016-03-01 |
拜耳製藥公司 |
作為ｅｐ４配體之新穎苯并咪唑衍生物
|
|
TW201623277A
(zh)
|
2014-03-26 |
2016-07-01 |
安斯泰來製藥股份有限公司 |
醯胺化合物
|
|
US10052332B2
(en)
|
2014-04-29 |
2018-08-21 |
Emory University |
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
|
|
CN106572993B
(zh)
|
2014-05-23 |
2019-07-16 |
卫材R&D管理有限公司 |
Ep4拮抗剂在制备治疗癌症的药物中的应用
|
|
SG11201609981RA
(en)
|
2014-06-04 |
2016-12-29 |
Thomas Helledays Stiftelse För Medicinsk Forskning |
Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
|
|
WO2016021742A1
(en)
|
2014-08-07 |
2016-02-11 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds as ep4 receptor antagonists
|
|
TWI712595B
(zh)
|
2015-01-09 |
2020-12-11 |
日商小野藥品工業股份有限公司 |
三環性螺化合物
|
|
CN108368127B
(zh)
|
2015-07-23 |
2020-12-11 |
武田药品工业株式会社 |
化合物及其作为ep4受体拮抗剂的用途
|
|
US10316040B2
(en)
|
2015-10-16 |
2019-06-11 |
Eisai R&D Management Co., Ltd. |
EP4 antagonists
|
|
CR20180323A
(es)
|
2015-11-20 |
2018-08-06 |
Idorsia Pharmaceuticals Ltd |
Derivados de indol n-sustituídos como moduladores de los receptores de pge2
|
|
EP4219462A1
(en)
|
2016-07-13 |
2023-08-02 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
LT3625224T
(lt)
|
2017-05-18 |
2021-10-25 |
Idorsia Pharmaceuticals Ltd |
N-pakeistieji indolo dariniai
|
|
CN110621671A
(zh)
|
2017-05-18 |
2019-12-27 |
爱杜西亚药品有限公司 |
作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
|
|
LT3625222T
(lt)
|
2017-05-18 |
2021-11-10 |
Idorsia Pharmaceuticals Ltd |
Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai
|
|
PT3625228T
(pt)
|
2017-05-18 |
2021-09-16 |
Idorsia Pharmaceuticals Ltd |
Derivados de pirimidina como moduladores dos recetores de pge2
|
|
TW201900180A
(zh)
|
2017-05-18 |
2019-01-01 |
瑞士商愛杜西亞製藥有限公司 |
嘧啶衍生物
|